Navigation Links
Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
Date:1/28/2009

EAST BRUNSWICK, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its biologics license application (BLA) for pegloticase for treatment-failure gout will be reviewed by the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) on March 5, 2009 as required for a drug of a new therapeutic class.

Savient submitted its BLA to the FDA on October 31, 2008 seeking approval to market pegloticase in the United States. On December 29, 2008, the FDA accepted the BLA filing for review and granted priority review. A priority review is an FDA designation that is assigned to products that if approved, would provide a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a serious or life-threatening disease. Under priority review, the target date for an FDA decision on the pegloticase BLA is April 30, 2009.

Savient's filing includes data from both the six-month placebo-controlled Phase 3 pivotal trials, as well as data from the open label extension (OLE) study. The two replicate six-month Phase 3 clinical trials for pegloticase were performed under the auspices of a Special Protocol Assessment (SPA) (2006). Pegloticase was granted orphan drug designation by the FDA in 2001.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and t
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... 20, 2014  AnaptysBio, Inc., a leader in ... announced the appointment of Marco Londei , ... lead the preclinical and clinical development of AnaptysBio,s ... pleased to welcome Dr. Londei to AnaptysBio,s executive ... and Chief Executive Officer of AnaptysBio. "Dr. Londei,s ...
(Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... cherry tree saplings were planted in Central Park of ... County Park System, located in Parsippany Troy-Hills.  The planting ... 100th anniversary of the historic gift of Japanese flowering ...  More than 75 Daiichi Sankyo employee volunteers partnered with ...
... 21, 2011 Solos Endoscopy, Inc. (OTCPK: SNDY) announced ... with sales revenues during the three months ended September ... for the third quarter is a result of instrument ... Centers and Surgery Centers across the United States. ...
Cached Medicine Technology:Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 2Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 3Daiichi Sankyo, Inc. Brings the Legacy of Washington, DC Cherry Trees to New Jersey 4Solos Endoscopy Finishes the 3rd Quarter Strong 2
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) ... The new module enables easy administration and routing of ... care. , This application allows users such as Therapists ... a to-do item to a specific client, categorize tasks ... reoccurring reminders for follow-ups. It's designed to enable ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Based ... are the only imaging assays capable of determining ... single test.  With these three dimensions of high-resolution ... to detect the widest range of disease-causing genetic ... missed by other genomic tools, including today’s advanced ...
Breaking Medicine News(10 mins):Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3
... home-based treatment for hand eczema is just as effective ... to // a new study. Eczema is an inflammatory ... scaling. ,Researchers examined 158 patients with moderate to ... About half the patients followed a home-based program taking ...
... therapy of acupuncture can help those suffering from arthritis ... ,A current multi-location trial included 570 patients ages ... were placed in three groups. One hundred and ninety ... followed a self-help course to manager their condition. The ...
... worldwide. A model based on the findings of a clinical ... severity of acute appendicitis, // according to a new study. ... 89 who underwent an appendectomy within three days of an ... the actual severity of acute appendicitis. The study showed CT, ...
... million people worldwide and is caused by abnormal surges in ... seizures. More than half of those with epilepsy can live ... is under way to determine just how effective surgery is ... epilepsy, the most common form of the disorder. Typically, about ...
... suggests getting active can help elderly patients who have trouble ... between the ages of 67 and 86 in a 90-minute ... exercise followed by 30 minutes of seated social activity and ... in the morning or in the evening, with all participants ...
... pain relief and improves function for people with ... effective complement to Normal care. This study was ... Alternative Medicine (NCCAM) and the National Institute of ... components of the National Institutes of Health.// The ...
Cached Medicine News:Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 2Health News:Acupunture relieves pain and improves function in knee Osteoarthritis 3
... An integrated approach to quality patient care., ... an innovative approach to anesthesia delivery. As ... combines enhanced ventilation features, electronically controlled gas ... and information management to create a truly ...
A non-adhering hydrogel sheet dressing for use on all partial and full thickness wounds (excluding 3rd degree burns.) Hydrogel sheet contains 96% water and 4% insoluble cross-linked polyethylene oxid...
... External Vacuum Therapy System restores sexual function ... Non-invasive and low cost vacuum therapy, coupled ... outcome", makes it the ideal therapy for ... System causes penile rigidity that can be ...
... D.O.R.C. Harmony Special Peristaltic phacoemulsification system features ... including individual programmability and remote control for ... a front panel with color coded function ... for ease of use and viewing. Under ...
Medicine Products: